Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...
we've benefited from extremely strong demand in China including from the expanded indication of Gardasil 9 to the 9- to 45-year age cohort in late 2022,” she explained. “In the second quarter, however ...
Courtney Breen, senior analyst of U.S. biopharmaceuticals at Bernstein, discusses Merck's slump in the market following its halt of Gardasil and HPV vaccine shipments in China. February 04, 2025 at ...
The biggest stories of the day delivered to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results